Vyome Holdings, Inc.
HIND Healthcare Biotechnology
In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.
Follow HIND
Vyome Holdings, Inc. (HIND) Altman Z-score
Vyome Holdings, Inc.'s Altman Z-score for fiscal 2025 is −22.00, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −22.00 | 41.09 |
| FY2024 | −63.09 | 23.35 |
| FY2023 | −86.44 | 4.13 |
| FY2022 | −90.57 | (135,524.76) |
| FY2020 | 135434.19 | (891,928.55) |
| FY2019 | 1027362.74 | (163,291.05) |
| FY2018 | 1190653.79 | (30,875,537.03) |
| FY2017 | 32066190.82 | 18,589,805.88 |
| FY2016 | 13476384.94 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.42 | — | 0.50 | |
| Retained earnings / total assets | (13.48) | — | −18.87 | |
| EBIT / total assets | (1.61) | — | −5.31 | |
| Market value of equity / total liabilities | 2.72 | — | 1.63 | |
| Sales / total assets | 0.05 | — | 0.05 | |
| Altman Z-score | Distress zone | −22.00 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −50.57 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | 3.0× |
| LPCN Lipocine Inc. compare | −7.7× |
| ALLR Allarity Therapeutics, Inc. compare | −10.5× |
| ICU SeaStar Medical Holding Corporation compare | −16.1× |
| HIND Vyome Holdings, Inc. | −22.0× |
| BCDA BioCardia, Inc. compare | −74.8× |
| CTXR Citius Pharmaceuticals, Inc. compare | — |
| RVLP RVL Pharmaceuticals PLC compare | — |
| CLVSQ Clovis Oncology, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets